A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations

BACKGROUND: A phase III trial was conducted to compare the safety and efficacy of erlotinib with that of gefitinib in advanced non-small cell lung cancer harbouring epidermal growth factor receptor mutations in exon 19 or 21. METHODS: Eligible patients were randomised to receive erlotinib (150 mg pe...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Cancer
Main Authors: Yang, J J, Zhou, Q, Yan, H H, Zhang, X C, Chen, H J, Tu, H Y, Wang, Z, Xu, C R, Su, J, Wang, B C, Jiang, B Y, Bai, X Y, Zhong, W Z, Yang, X N, Wu, Y L
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2017
Assuntos:
Clinical Study
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5344291/
https://ncbi.nlm.nih.gov/pubmed/28103612
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2016.456
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados